My interests include the discovery, engineering and in vitro characterization of high potential immunoglobulin fragments of therapeutic interest, and their subsequent advancement into the clinical translational pipeline. My expertise encompasses several selection technologies (e.g. Phage and Ribosome display), protein engineering, and the biophysical and in vitro cell characterization of protein drug candidates in a variety of formats (e.g. IgG, scFv-Fc, CAR, alternative scaffolds etc.)
I worked as a Senior research associate in Protein engineering at Molecular Partners AG, a Zürich-based pharmaceutical company, where I contributed to the discovery of several therapeutic protein drugs (‘DARPins’) now in clinical phases. I joined the Hi-TIDe in 2015.
In my PhD project, I am aiming to develop tools and resources to identify novel, non-TCR, pMHC targeting reagents with improved peptide-dependent selectivity. In concert, I am exploring the development of new in vitro phage display tools that will allow a better assessment of the potential cross-reactivity of any given pMHC-targeting molecule, whether native/orphan TCR, engineered TCR, or alternative binding reagent. With the focus on cancer neo-epitopes, the integration of these approaches may advance the development of personalized cancer therapeutics.
I joined the Hi-TIDe as a PhD student in July 2020 after completing my Bachelor’s and Master’s in Biochemistry at Charles University, Prague. During my master’s, I worked within the Laboratory of structural biochemistry of immune recognition at the Faculty of Science, where I focused on the preparation and characterization of novel bi-specific NK engagers with potential for cancer immunotherapy.
Human integrated tumor immunology discovery engine (Hi-TIDe)
Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne
Phone +41 21 692 59 51
Fax +41 21 692 59 95
Ch. des Boveresses 155